---
title: "恒大人寿三任董事长等 20 名高管被罚：涉保险资金运用、利益输送等"
description: "国家金融监督管理总局披露的罚单显示，恒大人寿保险有限公司 20 名相关责任人员被罚。就处罚案由来看，罚单显示，恒大人寿相关责任人员存在保险资金运用严重不合规、向关联方输送利益，投后管理不合规，报送的报告报表存在虚假记载等违法违规行为。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/257088359.md"
published_at: "2025-09-12T11:07:01.000Z"
---

# 恒大人寿三任董事长等 20 名高管被罚：涉保险资金运用、利益输送等

> 国家金融监督管理总局披露的罚单显示，恒大人寿保险有限公司 20 名相关责任人员被罚。就处罚案由来看，罚单显示，恒大人寿相关责任人员存在保险资金运用严重不合规、向关联方输送利益，投后管理不合规，报送的报告报表存在虚假记载等违法违规行为。

国家金融监督管理总局披露的罚单显示，恒大人寿保险有限公司 20 名相关责任人员被罚。就处罚案由来看，罚单显示，恒大人寿相关责任人员存在保险资金运用严重不合规、向关联方输送利益，投后管理不合规，报送的报告报表存在虚假记载等违法违规行为。

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | [Link](https://longbridge.com/zh-CN/news/276024005.md) |
| Shenhua Energy Gets Securities Regulator's Nod for Share Placement Plan | Shenhua Energy Gets Securities Regulator's Nod for Share Placement Plan | [Link](https://longbridge.com/zh-CN/news/275851575.md) |
| Sino Biopharm Wins China Nod for New Lung Cancer Use of PD-L1 Drug | Sino Biopharmaceutical has received Chinese regulatory approval for its PD-L1 inhibitor, benmelstobart, for use as maint | [Link](https://longbridge.com/zh-CN/news/276016059.md) |
| Canada's Manulife Q4 core earnings rise 5% | Canada's Manulife reported a 5% year-over-year increase in Q4 core earnings, with adjusted EPS surpassing analyst expect | [Link](https://longbridge.com/zh-CN/news/275667029.md) |
| Retal Urban Development Signs SSA With Alfozan Holding For Ajdan Co Shares | Retal Urban Development Company SJSC :RETAL URBAN DEVELOPMENT - SIGNS SHARE SWAP AGREEMENT WITH ALFOZAN HOLDING FOR AJDA | [Link](https://longbridge.com/zh-CN/news/275995528.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。